1 PGRx: An Interactive Software System for Integrating Clinical Genotyping with Prescription Drug Safety Assurance. Michael D. Kane, Ph.D. Assistant Professor.

Slides:



Advertisements
Similar presentations
Drug Information for Consumers and Healthcare Professionals Food and Drug Law Institute Annual Meeting Alan Goldhammer, PhD Associate VP Regulatory Affairs.
Advertisements

PERSONALIZED MEDICINE: Planning for the Future You, Your Biomarkers and Your Rights.
Taking Research and Development to the Clinic: Issues for Physicians AAAS/FDLI Colloquium I Diagnostics and Diagnoses Paths to Personalized Medicine Howard.
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning” A Report of the American College of Cardiology Foundation Task Force on Clinical.
10/20/ The Pharmaceutical Industry and Their Influence on Pain Management in the ED J. David Haddox, DDS, MD VP, Risk Management & Health Policy.
FDA Pharmacogenetic Labels A Clinical Perspective David A Flockhart MD, PhD Indiana University School of Medicine Clinical Pharmacology Subcommittee of.
Pavel Tarlykov, PhD General Genetics LTD Astana, Kazakhstan Raleigh, 2014.
Walsall Healthcare NHS Trust Medicines Management.
Disease State Management The Pharmacist’s Role
Mktg. 395 Internet Marketing Final Project Michael Abbo, Nancy Daniels, Anthony Medrano “In the future your doctor will be the middle man, mediating between.
Personalized Medicine: Using a patient’s genomic information (as well as other physiological parameters) to improve the safety and efficacy of pharmacological.
Drug Utilization Review (DUR)
2.11 Conduct Medication Management University Medical Center Health System Lubbock, TX Jason Mills, PharmD, RPh Assistant Director of Pharmacy.
Innovations: Using a Clinical Pharmacist as a Vehicle for Successful P4P Outcomes Lisa Meland, B.S., PharmD. Helen Pervanas, R.Ph. WellPoint-WellPoint.
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
Clinical Pharmacist Intervention in Cardiac Patients With Renal Impairment Elham Al-Shammari, B.Sc. Pharm. Hisham Abou-Auda, Ph. D. Meshal Al-Mutairi,
What Do Toxicologists Do?
Clinical Genotyping and Personalized Medicine Michael D. Kane, PhD (1) Associate Professor of Bioinformatics (2) University Faculty Scholar (3) Chair of.
Genetic Testing in Genomic Medicine Gail H. Vance M.D. Professor, Department of Medical & Molecular Genetics Indiana University School of Medicine.
Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.
Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.
University of Utah Department of Human Genetics Pharmacogenomics Louisa A. Stark, Ph.D. Director.
I MPACT OF P HARMACOGENOMICS ON THE P HARMACEUTICAL I NDUSTRY Viktoriya Buchko American Institute of Chemical Engineers August 6, 2008.
Introduction to Precision Medicine
 Definitions  Goals of automation in pharmacy  Advantages/disadvantages of automation  Application of automation to the medication use process  Clinical.
Pharmacovigilance Programme of India
The Emergency Pharmacist (EPh): A Safety Measure in Emergency Medicine Supported by The Agency for Healthcare Research and Quality, Partnerships in Patient.
The University of Mississippi Medical Center
Introduction to Pharmacoinformatics
Pharmacogenomics. Developing drugs on the basis of individual genetic differences Tailoring therapies to genetically similar subpopulations results in.
Basma Y. Kentab MSc.. 1. Define ambulatory care 2. Describe the value of ambulatory care practices 3. Explore pharmacy services in some ambulatory care.
Increasing Pharmacists reporting of adverse medication incidents Being Ready for new risks and Opportunities Prepared by Tim Garrett Northern Sydney Central.
ADVERSE EFFECTS OF DRUGS Phase II May Adverse Drug Reaction An adverse reaction to a drug is a harmful or unintended response. ADRs are claimed.
PHARMACOVIGILANCE AND CLINICAL TRIALS DIVISION 20 August 2015 Victoria Falls Protecting Your Right to Quality Medicines and Medical Devices.
Clinical Pharmacy Part 2
Biomedical Research Objective 2 Biomedical Research Methods.
Biomedical Research.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Indiana Institute For Personalized Medicine David A Flockhart MD, PhD Professor of Medicine, Genetics and Pharmacology Indiana University.
Florida Agency for Health Care Administration Florida Center for Health Information and Policy Analysis Florida Public Health Association - Medical Director’s.
Integrated Biomedical Information for Better Health Workprogramme Call 4 IST Conference- Networking Session.
Pharmacogenetics & Pharmacogenomics Personalized Medicine.
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
Clinical Decision Support Systems Paula Coe MSN, RN, NEA-BC NUR 705 Informatics and Technology for Improving Outcomes in Advanced Practice Nursing Dr.
Personalized Medicine Dr. M. Jawad Hassan. Personalized Medicine Human Genome and SNPs What is personalized medicine? Pharmacogenetics Case study – warfarin.
Medication Error Reduction Principles in Practice Copyright © – Academy of Managed Care Pharmacy (AMCP)Slide 1.
Pharmacogenetics.
Challenges to drug design Did you know? Over 2 million people are hospitalized each year for adverse reactions to prescription drugs. Over 2 million.
Single Competency Framework for Prescribers National Prescribing Centre (2012)
Consumer Advocate Perspective Clinical Trials Registration Sharon F. Terry, JAM Sharon F. Terry, JAM President and CEO, Genetic Alliance, Inc. Founding.
Applying New Science to Drug Safety Janet Woodcock, M.D. Acting Deputy Commissioner for Operations April 15, 2005.
© 2015 Omnicell, Inc. Content is confidential and proprietary 1 Multimed Adherence Packaging Your Pharmacy Logo Goes Here.
Pharmacogenomics: Improving the Dynamic of Care in Medication Management 1.
MTM Medication Therapy Management. What is Medication Therapy Management? From 1996 to 2006, the number of prescription medications dispensed increased.
 Pharmaceutical Care is a patient-centered, outcomes oriented pharmacy practice that requires the pharmacist to work in concert with the patient and.
1 Mobile Health Plus+ Presented by: Amaresh Sahoo (SIMSR, PGDM ) Prashant Gianani (SIMSR, PGDM )
27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.
Professor Orla Hardiman HRB Clinician Scientist Innovation Its role in Delivering Better Health Outcomes.
Drug Utilization Review & Drug Utilization Evaluation: An Overview
Pharmacy orientation PPP211 Lec. 2 (Pharmacy Career)
Medication therapy management
Pharmacogenomics Rita Leone, RN, MSN, CMSRN.
TOWARDS ELECTRONIC PHARMACOGENOMIC ASSISTANCE AND TRANSLATION SERVICES
Introduction to Clinical Pharmacy
electronic PharmacoGenomics Assistant (ePGA)
Pharmacogenomics Genes and Drugs.
Pharmacy practice experience I
Personalised Medicine ‘into the future’
Objective 2 Biomedical Research Methods
Introduction to Pharmacogenetics
Presentation transcript:

1 PGRx: An Interactive Software System for Integrating Clinical Genotyping with Prescription Drug Safety Assurance. Michael D. Kane, Ph.D. Assistant Professor of Computer and Information Technology Lead Genomic Scientist, Bindley Bioscience Center Purdue University Experience: Preclinical R&D Pharmaceutical Industry, VP of R&D in Genomics-Biotechnology Industry. Expertise: Genomics Technology, Bioinformatics, Pharmacology.

2 Emerging Landscape of Clinical Genotyping Enabling Opportunities Human Genome is Complete Genotyping Technologies are “Everywhere” Confirmed Links between Allelic Variants and Clinical Outcomes is Growing Hindrances to Implementation Consumers have Reservations About the Use of Their DNA Limited knowledge about Genomics in Healthcare Professional Practices Cost-Benefit for Disease Prognostics is Uncertain

3 Costs of Adverse Drug Responses (ADR)  According to a survey published in the Journal of American Pharmacists Association in 2001, the cost of drug-related mortality and morbidity in the US was estimated at over $175 billion in  ADRs represents approximately 10% of all health care costs in the US.  It is estimated that adverse drug reactions are the cause of over 200,000 deaths each year and is among the top 10 causes of death in the US.  McKesson is the world’s largest distributor of drugs and the largest healthcare software and IT company, a Fortune 18 company with $93 billion in revenues in THIS IS WHERE THE OPPORTUNITIES EXIST TO INTEGRATE CLINICAL GENOTYPING WITHIN HEALTHCARE

4 What does the PGRx System Do? Utilizes patient-specific genotyping to predict and prevent adverse drug responses. Supports the prescription drug process from physician to pharmacist to consumer. The system behaves similar to a “Drug-drug interaction” system, but can be described as a “Gene-drug interaction” system with detailed training components.

5 Why Pharmacy & Drug Safety? Based on Known Monogenic Traits –Phase-1 oxidative enzymes with known SNPs –Characterization of In vitro (& In vivo?) effects of SNPs is relatively simple Immediate Impact on Point-of-Care Therapeutics –Response to SNP data is easily “translated” to patient drug choice and dosing options –Addresses adverse idiopathic drug responses

6 Why Pharmacy & Drug Safety? Relatively Limited Ethical and Information Security Concerns –Knowledge of a patient's predisposition to altered drug clearance is a financial benefit to consumer, HMO, pharma, etc. –Patient-specific CYP-SNP data is amenable to “low security” web-based access supporting “travel incident” justification. Utilizes Established Information Management Logistics –“Drug-Drug” interactions management augmented with “Gene-Drug” interaction risk. - New Warfarin Label includes SNP-Clearance Data (8/16/07) –Roche (Affymetrix) AmpliChip for 2D6 genotyping (12/23/04) approved by FDA

7 PGRx is both Operational and Educational The software system integrates patient-specific genotypic and physiological information to predict the risk of ADRs. ADRs include: –Inadvertent overdosing due to poor metabolism. –Inadvertent under-dosing due to increased metab. –Inadvertent under-dosing due to decreased pro-drug bioactivation due to poor metab. The software includes a “mock” patient population that represents all clinically relevant genetic alleles relevant to drug metabolism. The software includes all FDA approved drugs and formulations.

8 PGRx is both Operational and Educational (continued) The software system includes detailed training components about each allelic variant (specific DNA changes, effects on protein/enzyme, etc.) The software system includes the ability to alter physiological variables in the “mock” population to allow the user to better understand the relationship between a patients physical status relevant to drug clearance variables (age, weight, volume of distribution, etc.) with allelic variations and ADR risk.

9

10 Implementation & Users The practicing pharmacist will likely be the first operational and educational user of the PGRx system, followed by physicians. The value proposition for the PGRx system lies in partnerships with established healthcare software companies, particularly those who support prescription drug dispensing.

11 CONTACT INFO: Michael D. Kane, Ph.D. Department of Computer and Information Technology, Lead Genomic Scientist, Bindley Bioscience Center, Purdue University, West Lafayette, IN (765)